Auto-Injectors Market
Number of pages: 100 | Report Format: PDF | Published date: October 17, 2022
Historical Years – 2020 | Base Year – 2021 | Forecasted Years – 2022-2030
|
Report Attribute |
Details |
|
Market size value in 2021 |
US$ 48 billion |
|
Revenue forecast in 2030 |
US$ 191.21 billion |
|
Growth Rate |
CAGR of 16.60% from 2022 to 2030 |
|
Base year for estimation |
2021 |
|
Forecast period |
2022-2030 |
|
Segments covered |
Product type, disease indication, end-user, and region. |
|
Regional scope |
North America, Europe, Asia Pacific, and the Rest of the World (ROW) |
According to the deep-dive market assessment study by Growth Plus Reports, the Global Auto-Injectors Market was valued at US$ 48 billion in 2021. The market is expected to register a revenue CAGR of 16.60% from 2022 to 2030.
Market Fundamentals
Auto-injectors are injectable medical devices that use prefilled cartridges or syringes powered by a spring system that can deliver drugs intramuscularly or subcutaneously. The main advantages of these devices are self-administration, increased patient compliance, lowered anxiety levels, and dosage precision. These devices can be used for immediate treatment of conditions such as anaphylaxis, migraine, etc., and chronic diseases like psoriasis, diabetes, multiple sclerosis, rheumatoid arthritis, and multiple sclerosis.
[453434]
Market Dynamics
The increase in the demand for targeted therapies and self-administration is the major factor driving the global auto-injectors market. Moreover, the rise in the instances of anaphylaxis, migraine, and chronic conditions such as diabetes, rheumatoid arthritis, and multiple sclerosis also propel the market revenue growth. Auto-injectors provide several advantages, such as dosage quality with increased efficacy, decreasing phobia related to needles, decrease in needlestick accidents, and dosage accuracy. Additionally, the rise in the research & development activities related to biologics and their rising approval is increasing the demand for auto-injectors. The adoption of advanced technologies, the expiration of biologics patents, and the investments by major players in the production of cost-effective and reusable devices, are also expected to drive the revenue growth of the global auto-injectors market. However, the availability of alternatives such as oral tablets, nasal sprays, and jet injectors, along with the stringent regulations and the high cost of auto-injectors are expected to hamper the market revenue growth to some extent.
Market Ecosystem
The global auto-injectors market is analyzed from four perspectives: product type, disease indication, end-user, and region.
Auto-Injectors Market by Product Type
[634242]
Based on product type, the global auto-injector market is segmented into disposable and reusable auto-injectors.
The disposable auto-injectors segment accounts for the largest revenue share in the global auto-injectors market. The large revenue share of disposable auto-injectors is attributed to their ease of use. Moreover, increasing investments by biopharma companies in developing cutting-edge technologies to improve the effectiveness and safety of these disposable auto-injectors is also expected to boost the market revenue growth rate.
Auto-Injectors Market by Disease Indication
Based on disease indication, the global auto-injectors market is segmented into rheumatoid arthritis, multiple sclerosis, diabetes, anaphylaxis, and other therapies.
Anaphylaxis disease indication segment accounts for the largest market revenue share in the global auto-injectors market. The dominance of the anaphylaxis segment can be attributed to the rising prevalence of allergic reactions to foods, medicines, insect stings & bites, and latex. The World Allergy Organization (WAO) estimates that anaphylaxis occurs between 50 and 112 times for every 100,000 people and estimates that the annual lifetime prevalence ranging from 0.3% to 5.1%. The initial course of treatment for anaphylaxis is epinephrine; thus, there is a rise in the adoption of advanced technologies.
Auto-Injectors Market by End-user
Based on end-user, the global auto-injectors market is segmented into hospitals, home care, and others.
The home care segment accounts for the largest market revenue share because of the rise in the demand for self-administration, and the rising incidence of anaphylaxis and diabetes. Another major driver for market revenue is the rise in the geriatric population globally.
Auto-Injectors Market by Region
Based on region, the global auto-injectors market is segmented into North America, Europe, Asia Pacific, and the Rest of the World.
North America dominated the global auto-injectors market in terms of revenue share, followed by Europe and the Asia Pacific. This large revenue share of North America in the global auto-injector market can be attributed to the rising incidence of anaphylaxis due to allergies.
According to the Asthma and Allergy Foundation of America, about 50 million people in the U.S. experience some allergy, every year. Moreover, conditions such as food allergies are among the most common health problems affecting children in the United States. Around 90,000 people visit the emergency room due to anaphylaxis caused by food. The presence of developed healthcare infrastructure, high healthcare expenditure, and top market players in the region are likely to support the market revenue growth in this region.
Competitive Landscape
The major players in the global auto-injectors market are:
Strategic Developments
The global auto-injectors market value is projected to reach US$ 191.21 billion in 2030.
The rise in the adoption of advanced technologies, increasing prevalence of anaphylaxis, and chronic conditions are the major factors driving the global auto-injectors market revenue growth.
Mylan N.V., AbbVie Inc., Eli Lilly and Company, Amgen Inc., Becton, and Dickinson and Company are among the key companies operating in the global auto-injectors market.
During the forecast period from 2022 to 2030, the revenue CAGR of the global auto injector market is expected to be 16.6%.
North American accounts for the largest revenue share, followed by Europe, while the Asia Pacific is the fastest-growing region in the global auto-injectors market.
*Insights on financial performance are subject to availability of the information in the public domain